Oral Answers to Questions

Jim Shannon Excerpts

Thursday 20th April 2017 Commons Chamber

[Andrea Leadsom]

I can assure the hon. Lady that the Government are looking at all possible areas both to reduce emissions of noxious substances such as nitrogen oxide and to ensure that we have good mitigation across the board to try to support ordinary working families. All types of mitigation are on the table.

[Jim Shannon (Strangford) (DUP)]

Northern Ireland has very low air pollution with all areas in the low pollution band, but it is essential that the national framework is truly nationwide and encompasses Northern Ireland. What discussions has the Secretary of State had with her counterpart in the Northern Ireland Assembly to ensure that that happens?

[Andrea Leadsom]

I can absolutely assure the hon. Gentleman that we have had discussions right across the devolved Administrations on this subject. The UK Government and all the devolved Administrations take it very seriously. We are working together closely and we will make an announcement in due course.

--- Later in debate ---

[Sir Edward Leigh]

I can indeed. This is a very serious matter that everybody wants to improve, so the Public Accounts Committee followed up on the National Audit Office investigation and recommended that the Department of Health and NHS England make better use of their buying power in order to pay a fair price for cancer drugs and improve data on patient outcomes. The NAO also followed up on several related issues in an April 2016 report. It recommended that the Department and NHS England should, in collaboration with the National Institute for Health and Care Excellence, consider affordability and ensure best prices for high-cost drugs.

[Jim Shannon (Strangford) (DUP)]

The findings show that although 40 cancer drugs were available through the cancer drugs fund in 2013-14 and 2014-15, some 71% of patients were covered by the 10 most common drugs. Does the hon. Gentleman agree that surely that indicates a need to move those 10 drugs on to the NHS list? Does he believe those findings have had any effect on Government policy on cancer drugs and the cancer drugs fund?

[Sir Edward Leigh]

Which drugs are approved by NICE is of course not a matter for the Comptroller and Auditor General, but I hear what the hon. Gentleman says. He makes his point well and I am sure the House has heard it.